DE60217804D1 - Fusionsprotein mit erhöhter in vivo Erythropoietinaktivität - Google Patents

Fusionsprotein mit erhöhter in vivo Erythropoietinaktivität

Info

Publication number
DE60217804D1
DE60217804D1 DE60217804T DE60217804T DE60217804D1 DE 60217804 D1 DE60217804 D1 DE 60217804D1 DE 60217804 T DE60217804 T DE 60217804T DE 60217804 T DE60217804 T DE 60217804T DE 60217804 D1 DE60217804 D1 DE 60217804D1
Authority
DE
Germany
Prior art keywords
fusion protein
epo
increased
erythropoietin activity
activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60217804T
Other languages
English (en)
Other versions
DE60217804T2 (de
Inventor
Dong-Eok Lee
Myung-Suk Oh
Ki-Wan Kim
Bo-Sup Chung
Ji-Sook Park
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CJ CheilJedang Corp
Original Assignee
CJ Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CJ Corp filed Critical CJ Corp
Publication of DE60217804D1 publication Critical patent/DE60217804D1/de
Application granted granted Critical
Publication of DE60217804T2 publication Critical patent/DE60217804T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Plant Pathology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE60217804T 2001-12-03 2002-08-14 Fusionsprotein mit erhöhter in vivo Erythropoietinaktivität Expired - Lifetime DE60217804T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2001-0075994A KR100467751B1 (ko) 2001-12-03 2001-12-03 생체내 에리스로포이에틴 활성이 증진된 융합단백질
KR2001075994 2001-12-03

Publications (2)

Publication Number Publication Date
DE60217804D1 true DE60217804D1 (de) 2007-03-15
DE60217804T2 DE60217804T2 (de) 2007-09-13

Family

ID=36123483

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60217804T Expired - Lifetime DE60217804T2 (de) 2001-12-03 2002-08-14 Fusionsprotein mit erhöhter in vivo Erythropoietinaktivität

Country Status (17)

Country Link
US (1) US7091326B2 (de)
EP (1) EP1316561B1 (de)
JP (1) JP4035400B2 (de)
KR (1) KR100467751B1 (de)
CN (1) CN100400548C (de)
AT (1) ATE352565T1 (de)
AU (1) AU2002300734B2 (de)
BR (1) BR0203386A (de)
CA (1) CA2400908C (de)
DE (1) DE60217804T2 (de)
ES (1) ES2280487T3 (de)
MX (1) MXPA02008454A (de)
NZ (1) NZ520776A (de)
RU (1) RU2232192C2 (de)
TW (1) TWI243827B (de)
WO (1) WO2003048210A1 (de)
ZA (1) ZA200206879B (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7345019B1 (en) * 1999-04-13 2008-03-18 The Kenneth S. Warren Institute, Inc. Modulation of excitable tissue function by peripherally administered erythropoietin
US20030072737A1 (en) * 2000-12-29 2003-04-17 Michael Brines Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
US7767643B2 (en) 2000-12-29 2010-08-03 The Kenneth S. Warren Institute, Inc. Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs
US7645733B2 (en) * 2003-09-29 2010-01-12 The Kenneth S. Warren Institute, Inc. Tissue protective cytokines for the treatment and prevention of sepsis and the formation of adhesions
CN100516225C (zh) * 2004-07-30 2009-07-22 成都地奥制药集团有限公司 人血清蛋白与促红细胞生成素的融合蛋白
UA100222C2 (uk) * 2005-08-05 2012-12-10 Араім Фармасьютікалз, Інк. Тканинозахисні пептиди і їх застосування
US7625564B2 (en) 2006-01-27 2009-12-01 Novagen Holding Corporation Recombinant human EPO-Fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo
US9458444B2 (en) 2006-02-03 2016-10-04 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US10221228B2 (en) 2006-02-03 2019-03-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US20140113860A1 (en) 2006-02-03 2014-04-24 Prolor Biotech Ltd. Long-acting polypeptides and methods of producing and administering same
US20150038413A1 (en) 2006-02-03 2015-02-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US9249407B2 (en) 2006-02-03 2016-02-02 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US8048849B2 (en) 2006-02-03 2011-11-01 Modigene, Inc. Long-acting polypeptides and methods of producing same
US10351615B2 (en) 2006-02-03 2019-07-16 Opko Biologics Ltd. Methods of treatment with long-acting growth hormone
US7553940B2 (en) * 2006-02-03 2009-06-30 Modigene Inc Long-acting EPO polypeptides and derivatives thereof and methods thereof
US8946155B2 (en) 2006-02-03 2015-02-03 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
CN100436482C (zh) * 2006-04-14 2008-11-26 东莞太力生物工程有限公司 长效人促红细胞生成素融合蛋白及其制备和纯化方法
BRPI0814465B1 (pt) 2007-07-26 2021-11-23 Novagen Holding Corporation Proteína de fusão, dímero, método para produzir uma proteína de fusão, linhagem de célula, usos de uma proteína de fusão e de uma composição farmacêutica e composição farmacêutica
US9663778B2 (en) 2009-07-09 2017-05-30 OPKO Biologies Ltd. Long-acting coagulation factors and methods of producing same
CN102994547B (zh) * 2011-09-08 2015-05-13 哈药集团技术中心 重组人促红素-ctp融合蛋白生产工艺及应用
CN103182073A (zh) * 2011-12-29 2013-07-03 哈药集团技术中心 一种重组人干扰素α-CTP融合蛋白的药物注射剂
PE20142405A1 (es) 2012-04-19 2015-01-25 Opko Biolog Ltd Variantes de oxintomodulina de accion prolongada y metodos de produccion de las mismas
SG10202010383YA (en) * 2012-11-20 2020-11-27 Opko Biologics Ltd Method of increasing the hydrodynamic volume of polypeptides by attaching to gonadotrophin carboxy terminal peptides
EP2968391A1 (de) 2013-03-13 2016-01-20 Moderna Therapeutics, Inc. Langlebige polynukleotidmoleküle
US20150158926A1 (en) 2013-10-21 2015-06-11 Opko Biologics, Ltd. Long-acting polypeptides and methods of producing and administering same
RU2021103436A (ru) * 2014-12-10 2021-02-25 Опко Байолоджикс Лтд. Способы производства ctp-модифицированных полипептидов гормона роста длительного действия
CN108289851B (zh) 2015-06-19 2021-06-01 Opko生物科学有限公司 长效凝固因子及其产生方法
KR20240006077A (ko) 2016-07-11 2024-01-12 옵코 바이오로직스 리미티드 지속성 응고 인자 vii 및 그 제조 방법
CN110393801A (zh) * 2018-04-24 2019-11-01 中国科学院上海生命科学研究院 靶向促黄体生成素促进机体造血的应用
CN112175088B (zh) * 2019-07-02 2023-03-28 江苏晟斯生物制药有限公司 改进的fix融合蛋白、缀合物及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6225449B1 (en) * 1991-10-04 2001-05-01 Washington University Hormone analogs with multiple CTP extensions
WO1990009800A1 (en) * 1989-02-21 1990-09-07 Washington University Modified forms of reproductive hormones
US5856298A (en) * 1989-10-13 1999-01-05 Amgen Inc. Erythropoietin isoforms
JP4156024B2 (ja) * 1993-04-20 2008-09-24 ワシントン ユニバーシティー 修飾されたタンパク質及びペプチド医薬品
ZA946122B (en) 1993-08-17 1995-03-20 Amgen Inc Erythropoietin analogs
PE20010288A1 (es) * 1999-07-02 2001-03-07 Hoffmann La Roche Derivados de eritropoyetina
CZ299516B6 (cs) 1999-07-02 2008-08-20 F. Hoffmann-La Roche Ag Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem
JP4944324B2 (ja) 1999-07-13 2012-05-30 ボルダー バイオテクノロジー， インコーポレイテッド 免疫グロブリン融合タンパク質
CA2391080A1 (en) 1999-11-12 2001-05-25 Merck Patent Gesellschaft Mit Beschraenkter Haftung Erythropoietin forms with improved properties
DE60117919T2 (de) 2000-12-11 2006-12-14 Cheil Jedang Corp. Fusionsprotein mit verbesserter in vivo erythropoietinwirkung

Also Published As

Publication number Publication date
EP1316561A1 (de) 2003-06-04
CA2400908A1 (en) 2003-06-03
MXPA02008454A (es) 2005-08-26
ES2280487T3 (es) 2007-09-16
KR20030045341A (ko) 2003-06-11
ZA200206879B (en) 2003-04-29
ATE352565T1 (de) 2007-02-15
JP4035400B2 (ja) 2008-01-23
AU2002300734B2 (en) 2009-01-08
RU2232192C2 (ru) 2004-07-10
CN1422870A (zh) 2003-06-11
KR100467751B1 (ko) 2005-01-24
EP1316561B1 (de) 2007-01-24
CA2400908C (en) 2011-04-12
US20030113871A1 (en) 2003-06-19
BR0203386A (pt) 2004-05-25
NZ520776A (en) 2004-02-27
TWI243827B (en) 2005-11-21
US7091326B2 (en) 2006-08-15
JP2003189853A (ja) 2003-07-08
WO2003048210A1 (en) 2003-06-12
DE60217804T2 (de) 2007-09-13
CN100400548C (zh) 2008-07-09

Similar Documents

Publication Publication Date Title
DE60217804D1 (de) Fusionsprotein mit erhöhter in vivo Erythropoietinaktivität
ATE320449T1 (de) Fusionsprotein mit verbesserter in vivo erythropoietinwirkung
EP2557160A3 (de) Mutierte D-Aminotransferase und Verfahren zur Herstellung optisch aktiver Glutaminsäurederivate damit
AU4003999A (en) Healthbar formulations
NO2017028I2 (no) eftrenonacog alfa eller et biotilsvarende legemiddel ihht Artikkel 10(4) av Directive 2001/83/EC, som beskyttet av basispatentet.
RU2002123286A (ru) Слитый белок с увеличенной эритропоэтиновой активностью, нуклеиновая кислота, кодирующая слитый белок, и способ получения слитого белка
CY1112787T1 (el) Πολλαπλομερη του υποδοχεα κυτοκινης ζcytor17
DE69740096D1 (de) Pharmazeutische Zusammensetzung mit einem Exendin-4-Peptid
WO2003010176A3 (en) Protein-nucleic acid complexes
WO2007047829A3 (en) Novel heterodimeric proteins and uses thereof
DK1645566T3 (da) Parathyroidhormonanaloger
WO2005021579A3 (en) Epo mimetic peptides and fusion proteins
DE3853922D1 (de) Aminosäurederivate als Amphotere.
ES2075155T3 (es) Separacion enzimatica de una secuencia de una proteina con amino terminal.
FI96274C (fi) Menetelmä valmistaa pimobendaanin oraalisia lääkeainemuotoja
WO2002018443A3 (en) A recombinant monoclonal antibody to phosphotyrosine-containing proteins
EP1078921A4 (de) Intermediate und verfahren zur herstellung optisch aktiver oktansäure-derivate
AR025660A1 (es) PRECURSOR DE HIRUDINA, PROCEDIMIENTO PAA LA PREPARACIoN DE LEU-HIRUDINA Y SU EMPLEO PARA LA PREPARACIoN DE LEU-HIRUDINA.
DE59006688D1 (de) Substituierte Aminosäureamid-Derivate, deren Herstellung und Verwendung.
BR0111692A (pt) Processo para preparação de polipeptìdeo il-18 fisiologicamente ativo
EE200000487A (et) Kaspaas-8 proteaasiga interakteeruv proteiin, seda kodeeriv DNA järjestus, selle valmistamis- ja identifitseerimismeetod ning kasutamine ravimi valmistamiseks
DE50010629D1 (de) Gewebehalter
DE59903063D1 (de) Semi-hydrochlorid von 8-cyan-1- cyclopropyl -7-(1s,6s-2, 8-diazabicyclo 4.3.0]nonan -8-yl)-6- fluor-1, 4-dihydro-4- oxo-3- chinolincarbonsäure
CA2285700A1 (en) Renin-active substance
AU2003271452A1 (en) Modified glp-1 peptides with increased biological potency

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: CJ CHEIL JEDANG CORP., SEOUL, KR

8328 Change in the person/name/address of the agent

Representative=s name: LENZING GERBER STUTE PARTNERSCHAFTSGESELLSCHAFT VO